Search for content, post, videos

Acarix receives commercial order for CADScorSystem


Herning Hospital has placed the first commercial order for the CADScorSystem for non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD).

The CADScorSystem combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes.

“Despite the availability of improved risk stratification algorithms, the incidence of normal investigations such as nuclear or CT imaging remains high. We were therefore interested in testing the diagnostic accuracy of the CADScorSystem for ruling out CAD to see if it could be used to reduce demand for more advanced diagnostic modalities. We have concluded that, with its ability to rule out CAD with a 97% negative predictive value, this advanced, easy to use device could indeed have the potential to be deployed as a routine frontline test. We now look forward to explore the performance of the device in routine clinical use,” explained Morten Bøttcher, MD PhD FESC, head of the Cardiac Imaging center at the Hospital Unit West in Denmark and associate professor at Aarhus University.

“Coronary Artery Disease affects more than 120 million people worldwide but the current diagnostic pathway, which can rapidly escalate to expensive imaging and coronary angiography, is inefficient. We are very pleased that having thoroughly evaluated the CADScorSystem, Herning Hospital will become our first commercial customer. Dr. Bøttcher and his team have an international reputation for outstanding research in the area of Coronary Artery Disease and we look forward to continuing our close collaboration with them,” commented Acarix CEO Søren Rysholt Christiansen.